Conduction Disturbances after Percutaneous Aortic Valve Replacement Reducing Post-TAVR Conduction Disturbances UC201303178a EE Conduction Disturbances after TAVR • Anatomical Considerations • Conduction Disturbances and Pacemaker Implantation – Driving Factors – Patient Impact • Conclusions Anatomical Considerations • Conduction abnormalities are not atypical following TAVR due to the anatomical proximity of the aortic valve to the conduction system – Distance from the non-coronary cusp to the HIS bundle has been measured to be 6.3 ± 2.4 mm. Modified from Tawara. Igawa et. al, Jap Circ 2009 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. ©Medtronic, Inc. 2013. All Rights Reserved. Conduction Disturbances after TAVR • Anatomical Considerations • Conduction Disturbances and Pacemaker Implantation – Driving Factors – Patient Impact • Conclusions Mechanisms Driving Post-TAVR Conduction Disturbances More than 25 studies have been published on predictors of post-TAVR conduction disturbances (CDs) and permanent pacemaker implant (PPI) Patient-Related Factors • Male gender3 Anatomical Factors Procedural Factors (Device / Operator) • Age > 75 years9 • Variations in location of LBBB exit point1 • Radial force of the prosthesis3 • Previous MI3 • Septum thickness1,6 • Implant Depth2,3,7 • Right Bundle Branch Block (RBBB)2,3,4,5,7 • Thickness of the noncoronary cusp1 • Balloon Aortic Valvuloplasty8 • Other pre-existing conduction disturbances3,4,8,9 • Application of PPI guidelines10 • Learning Curve11 1Jilaihawi, et al. Am Heart J 2009; 2Munoz-Garcıa, et. al. JACC CV 2012; 3Piazza et. al. EuroIntervention 2010; 4De Carlo , et. al. Am Heart J 2012; 5Calvi, et. al. JICE 2011; et. al. Cath Card Intv 2012; 7Fraccarao, et. al. Am J Card 2011; 8Khawaja, et. al. Circ 2011; 9Schroeter et. al. EuroPACE 2011; 10Wenaweser, et. al. presented at EuroPCR 2013; 11Meredith, et. al. presented at TCT 2012 6Saia, INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. Patient-Related Drivers of Conduction Disturbances and Pacemaker Implantation Pre-existing Conduction Disturbances, including RBBB Pre-existing Conduction Disturbances • Degenerative Aortic Stenosis (AS) is associated with electrical conduction abnormalities because calcification in and around the aortic valve can progress and extend to involve the electrical conduction system of the heart • Rates of conduction disturbances at baseline are high in patients with AS • • • • Atrial Fibrillation 32% Hemiblock 23% LBBB 17% RBBB 17% Van Mieghem et. al., Ann Thorac Surg 2012 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. Pre-existing Conduction Disturbances • Pre-existing CDs may contribute to the development of post-TAVR arrhythmias which necessitate PPI • This chart demonstrates how pre-existing RBBB can contribute to the formation of 3°AV block if the patient develops LBBB during TAVR AV conduction at baseline: AV conduction after TAVI: AV conduction at follow-up: • Black boxes = pts w/o follow-up , ▪ # in parentheses = pts with PPI Roten et. al., Am J Card 2010 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. Procedural Drivers of Conduction Disturbances and Pacemaker Implantation Pre-implant BAV Contribution of TAVR Procedural Steps to Conduction Disturbances • ECG recording during individual TAVR steps showed that BAV may contribute half of the CDs that develop during TAVR. • Patients developing new CDs during BAV had a significantly higher balloon/annulus ratio (1.10 ± 0.10 vs. 1.03 ± 0.11, p=0.030)1 • 2%1 to 16%2 of PPI in TAVR may be due to CDs caused during BAV 1Nuis R. Eur Heart J. 2011;32(16):2067-2074. 2Grube E . JACC Cardiovasc Interv 2011;4(7):751-757. INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. Procedural Drivers of Conduction Disturbances and Pacemaker Implantation Pre-implant BAV Implant Depth INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. Implant Depth Impacts Conduction Disturbances • A lower (ventricular) position of the valve relative to the hinge point of the anterior mitral leaflet was associated with a higher incidence of new LBBB (35% vs. 0%, P = .029). Implanted Above → 0% of patients developed LBBB Hinge Point of the Anterior Mitral Valve Implanted Below → 35% of patients developed LBBB Gutierrez et al. Am Heart J 2009, (N=33) INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. ©Medtronic, Inc. 2013. All Rights Reserved. Implant Depth and PPI Rate Pacemaker Implants (% pts.) Data from independent studies plotted on the same graph show the strong relationship between PPI rate and implant depth 5 4 3 2 1 CoreValve Implant Depth (mm) 1Tchetche, et al. EuroIntervention 2012; 2Munoz-Garcıa, et. al. JACC CV 2012; 3Piazza et. al. EuroIntervention 2010; 4De Carlo , et. al. Am Heart J 2012; 5Calvi, et. al. JICE 2011; 6Saia, et. al. Cath Card Intv 2012; 7Fraccarao, et. al. Am J Card 2011; 8van der Boon, et. al. Int J Card 2013; INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. ©Medtronic, Inc. 2013. All Rights Reserved. CoreValve Procedural Outcomes at Target Implant Depth • 134 CoreValve patients treated at 2 experienced centers • All implants performed using the AccuTrak delivery system and a 4-6 mm target implant depth • Appropriately sized balloon used for pre-implant BAV N=134 Patients (%) Procedural Success 133 (99.2) BAV 129 (98.5) Balloon-Annulus Ratio 0.95 0.09 Depth of Implant 4.9 2 PVL > 2/4 0 (0) Central leak 0 (0) New LBBB 18 (13.4) New Transient or Sustained AVB 17 (12.7) New Pacemaker Implantation 12* (10.6) *12 of 113 patients without baseline pacemaker. Tchetche, et al; EuroIntervention 2012; e-publication. INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. ©Medtronic, Inc. 2013. All Rights Reserved. Procedural Drivers of Conduction Disturbances and Pacemaker Implantation Pre-implant BAV Implant Depth Variations in Application of Pacemaker Indications INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. ©Medtronic, Inc. 2013. All Rights Reserved. Application of PPI Guidelines • PPI for relative indications by some centers and not others, driven by the desire to mobilize patients quickly after TAVR, may be a reason for the variability in reported pacemaker rates Gillis et al HRS/ACCF Pacemaker Mode Selection INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. CoreValve ADVANCE | Permanent Pacemaker Implant Rate by Geography Varying 30-day pacemaker rates across geographies in the ADVANCE study may reflect differences in the application of PPI guidelines Countries with less than 15 implants not shown 1Wenaweser, et al. Presented at EuroPCR 2013 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. Absolute vs. Relative Pacemaker Indications • 258 CoreValve patients from Nov 2007 to Feb 2012 (Copenhagen, Denmark) • 9% with preexisting pacemaker • 19.7% of patients had an absolute pacemaker indication (3°and 2°AVB) • After periprocedural period only 9.8% of TAVR patients had an absolute pacemaker indication – 9.9% of conduction disturbances resolved Thygesen et al, London Valves 2012. INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. Procedural Drivers of Conduction Disturbances and Pacemaker Implantation Pre-implant BAV Implant Depth Variations in Application of Pacemaker Indications Learning Curve INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. Effect of Learning Curve on PPI Rate 100% The overall rate of PPI in the CoreValve Australia-New Zealand Study decreased over time as operators gained experience. 80% PPI Overall PPM =31.1% Recent experience = 17.2% 60% 40% 42.9% 39.7% 33.3% 20% 32.2% 24.6% 28.6% 26.1% 17.2% 0% Enrolling centers: Aug 08 Feb 09 Feb 09 Aug 09 Aug 09 Feb 10 Feb 10 Aug 10 Aug 10Feb 11 Feb 11 Aug 11 Aug 11 Feb 12 Feb 12 Oct 12 6 9 10 10 10 10 10 10 PPM rates in 6-mo blocks of pt enrollment, except most recent is 8-mo. 1Muller, et al. Presented at EuroPCR 2013 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. Conduction Disturbances after TAVR • Anatomical Considerations • Conduction Disturbances and Pacemaker Implantation – Driving Factors – Patient Impact • Conclusions Pacemaker Dependency Some TAVR-induced AV conduction disturbances may be transient1-9 van der Boon, et. al, 20136: • More than half of patients who had received a new pacemaker after CoreValve were pacemaker independent at follow-up (median time: 12 months). • Definition of pacemaker dependent: 1Piazza, • Presence of high degree AV block (HDAVB) • a slow (<30 bpm) or absent escape rhythm et al. JACC CV 2008; 2Gutierrez, et. al. Am Heart J 2009; 3Piazza et. al. EuroIntervention 2010; 4Guetta, et. al. Am J Cardiol 2011; et. al. Am J Card 2011; 6van der Boon, et. al. Int J Card 2013; 7Pereira, et. al. PACE 2013; 8Simms, et. al. ICVTS 2013; 9Franzoni, et al. Am J Card 2013 5Fraccarao, INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. Pacemaker Dependency Conduction abnormalities may resolve due to the transient nature of some TAVR-induced tissue injury Mechanical Injury Ischemic Injury • Wall tension due to radial force • Tissue compression during BAV • Procedural Inflammation • Hypotension during rapid pacing (BAV procedure) • Procedural Edema • Other hypotensive episodes INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. Clinical Impact of LBBB Post-TAVR • LBBB is typically associated with left ventricular dyssynchrony, ventricular remodeling, and impaired function7. • Several studies have looked at the impact of LBBB on cardiac function1,2 and mortality post-TAVR2-7. • There is no consensus in the field on impact of post-TAVR LBBB on mortality or cardiac function. • The frequency, degree, timing, and durability of CD recovery after TAVR is currently unknown. This variability may be driving inconsistent conclusions about the clinical impact of LBBB. 1Hoffmann, 2013; et. al. JACC CV Int 2012; 2Wenaweser, et al. Presented at EuroPCR 2013; 3Franzoni et. al. Am J Card 2013; 4De Carlo , et. al. Am Heart J 2012; 5Testa, et. al. Circ et. al. JACC 2012; 7Houthuizen, et. al. Circ 2012; 6Urena, INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. CoreValve ADVANCE | Impact of LBBB The ADVANCE study showed no significant difference in survival between those patients with a new LBBB post-implant and those without. 1Wenaweser, et al. Presented at EuroPCR 2013 INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. Current Research is Inconclusive Regarding Mortality Impact of LBBB Post –TAVR LBBB Post-TAVR Mortality Impact Patients not receiving permanent pacemaker before discharge. LBBB Post-TAVR NO Mortality Impact De Carlo, et. al. AHJ 2012, (N=275) Houthuizen, et. al. Circulation 2012, (N=679) Urena, et. al. JACC 2012, (N=202) Muller, et. al. EuroPCR 2013, (N=200) INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. ©Medtronic, Inc. 2013. All Rights Reserved. CoreValve ADVANCE | Impact of LBBB The ADVANCE study showed no significant adverse effect of a new LBBB at discharge on the mean LV ejection fraction post-TAVR 1 Year: p = 0.138 Post-Implant LBBB No Post-Implant LBBB 1Wenaweser, N=145 N=276 et al. Presented at EuroPCR 2013 N=115 N=222 N=119 N=216 N=102 N=224 For this analysis, no patient in either group had a pacemaker INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan. CoreValve ADVANCE | Survival by Pacemaker The ADVANCE study showed no significant difference in survival between those patients with a post-implant pacemaker and those without. 1Wenaweser, et al. Presented at EuroPCR 2013 INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. ©Medtronic, Inc. 2013. All Rights Reserved. Pacemaker Implantation Post-TAVR Not Associated With Increased Mortality Three additional large studies demonstrate no association between pacemaker implantation and mortality Buellesfeld, et. al. JACC 2012, (N=353) CoreValve ANZ Study, Muller, et. al. EuroPCR 2013, (N=476) De Carlo, et. al. AHJ 2012, (N=275) INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. ©Medtronic, Inc. 2013. All Rights Reserved. Conduction Disturbances after TAVR • Anatomical Considerations • Conduction Disturbances and Pacemaker Implantation – Driving Factors – Patient Impact • Conclusions INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. ©Medtronic, Inc. 2013. All Rights Reserved. Conclusions • Conduction abnormalities are not atypical following AVR and TAVR due to the anatomical proximity of the aortic valve to the conduction system • Rates of conduction abnormalities are high in patients with AS. These pre-existing conduction disturbances predict post-TAVR pacemaker implantation • Post-TAVR pacemaker implantation is not associated with an increase in mortality – The field has not reached consensus on the mortality effect of postTAVI LBBB. • Best practice in BAV sizing, depth of implant, and application of pacemaker implant guidelines can result in low rates of post-TAVR conduction disturbances CoreValve is a registered trademark of Medtronic CV Luxembourg S.a.r.l. For more information and a complete list of adverse events, warning and contraindications reference CoreValve IFU. INTERNATIONAL. CAUTION—For distribution only in markets where CoreValve has been approved. Not approved in the USA, Canada or Japan.